Medication-Related Osteonecrosis of the Jaws: Two Center Retrospective Cohort Studies

Table 1

Demographic and clinical characteristics.

Demographic and clinical characteristics
Characteristic	Value
Sample size	32 (100)
Gender
Male	11 (34.3)
Female	21 (65.6)
Age
Indication for medication
Malignant disease	21 (65.6)
Nonmalignant disease	11 (34.4)
Medication risk factors
Pamidronate	2 (6.2)
Zoledronic	24 (75)
Antiangiogenic agents	1 (3.1%)
Others (oral BPs)	6 (18.8)
Mode of delivery
IV	21(65.6)
IV + Oral	5 (15.6)
IV + (IV + Oral)	26 (81.25)
Oral	6 (18.8)
Anatomic Location
Mandibular	23 (71.9)
Maxillary	9 (28.1)
Maxilla and mandible	1 (3.1)
Treatment duration
Zoledronate	33.87 ± 23.05
Pamidronate	6±0
Others (oral BPs)	34.9±20.87
Antiangiogenic agents	18± 0
Etiology of MRONJ
Tooth extraction	29 (90.6)
Implant extraction	1 (3.1)
Spontaneously	2 (6.25)
Treatment modality
Surgical	18 (56.2)
Conservative	14(43.8)

(i) Data presented as n (%) or mean ± standard deviation.
BPs, bisphosphonate; IV, intravenous subcutaneous; MRONJ, medication-related osteonecrosis of the jaw; PO, oral.
(ii) Treatment duration: exemption as values present number of months.
(iii) Sums to >100% because some patients used multiple medications.
(iv) IV: intravenous regime; IV+PO: intravenous + oral; some of the patients received drugs by both ways.